IP Library Granted Patent US 8,211,368
Granted Patent B2
US 8,211,368 · App. 13/113,787 · Granted Jul 3, 2012

Conversion of nitrogen dioxide (NO

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,211,368
App. No.
13/113,787
Granted
Jul 3, 2012
Kind
B2
Abstract

A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal.

Claims (30)

1. A method of providing a therapeutic gas including nitric oxide to a mammal comprising:

connecting a permeation tube to a source of nitrogen dioxide via a diffusion cell;

connecting a receptacle to the permeation tube, the receptacle including an inlet, an outlet, and a surface-active material including an antioxidant, wherein the inlet is configured to receive the flow of nitrogen dioxide from the permeation tube;

diffusing gaseous nitrogen dioxide from the source of nitrogen dioxide into an air flow;

communicating the air flow to the outlet through the surface-active material; and

converting the gaseous nitrogen dioxide to nitric oxide at ambient temperature.

2. The method of claim 1 , wherein the source of nitrogen dioxide is liquid nitrogen dioxide.

3. The method of claim 1 , wherein the permeation tube length is scaled to provide a predetermined dose of nitrogen dioxide at a particular temperature.

4. The method of claim 1 , wherein the permeation tube further comprises a movable, non-permeable sheath over the length of the tube.

5. The method of claim 4 , further connecting the permeation tube to the diffusion cell through a diffusion needle.

6. The method of claim 5 , wherein the diffusion needle further comprises holes on the side of needle and an outer sheath surrounding the holes, wherein the sheath has slots fitted around the needle configured to be turned to uncover the uncover the desired hole.

7. The method of claim 1 , further connecting the diffusion cell to a plurality of permeation tubes through a plurality of narrow bore diffusion needles.

8. The method of claim 1 , wherein the surface-active material is coated with the antioxidant.

9. The method of claim 1 , wherein the surface-active material comprises a silica gel.

10. The method of claim 1 , wherein the antioxidant comprises ascorbic acid.

11. The method of claim 1 , wherein the antioxidant comprises alpha tocopherol or gamma tocopherol.

12. The method of claim 1 , wherein the receptacle is a first receptacle, the method further comprising connecting a second receptacle to the first receptacle, wherein the second receptacle is configured to receive the flow from the first receptacle and includes a second inlet, a second outlet, and a second surface-active material including an aqueous solution of an antioxidant and wherein the second inlet is configured and fluidly communicates the flow to the second outlet through the second surface-active material to convert the gaseous nitrogen dioxide to nitric oxide at ambient temperature.

13. A method of providing a therapeutic gas including nitric oxide to a mammal comprising:

connecting a pressure regulator to a source of nitrogen dioxide;

attaching a receptacle to the pressure regulator, the receptacle including an inlet, an outlet, and a surface-active material coated with an antioxidant, wherein the inlet is configured to receive the flow of nitrogen dioxide from the permeation tube;

communicating the flow to the outlet through the surface-active material;

converting the gaseous nitrogen dioxide to nitric oxide at ambient temperature; and

transporting the therapeutic gas to a mammal.

14. The method of claim 13 , further placing the receptacle on the low pressure side of the pressure regulator.

15. The method of claim 13 , the method further comprising connecting a second receptacle to the first receptacle, wherein the second receptacle is configured to receive the flow from the first receptacle and includes a second inlet, a second outlet, and a second surface-active material including an aqueous solution of an antioxidant and wherein the second inlet is configured and fluidly communicates the flow to the second outlet through the second surface-active material to convert the gaseous nitrogen dioxide to nitric oxide at ambient temperature.

16. The method of claim 13 , wherein the pressure regulator includes an inlet port and an outlet port that connects the receptacle with a gas bottle having nitrogen dioxide in air.

17. The method of claim 13 , wherein the surface-active material is coated with the aqueous solution of the antioxidant.

18. The method of claim 13 , wherein the surface-active material comprises a silica gel.

19. The method of claim 13 , wherein the antioxidant comprises ascorbic acid.

20. The method of claim 13 , wherein the antioxidant comprises alpha tocopherol or gamma tocopherol.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2026
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: VERO BIOTECH INC.
Reel/Frame 075308/0198 →
SECURITY INTEREST Recorded Mar 16, 2026
From: VERO BIOTECH INC.
To: SYMBIOTIC CAPITAL AGENCY LLC, AS COLLATERAL AGENT
Reel/Frame 075117/0935 →
SECURITY INTEREST Recorded Jan 3, 2024
From: VERO BIOTECH INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 066187/0865 →
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 3, 2024
From: RUNWAY GROWTH FINANCE CORP (F/K/A RUNWAY GROWTH CREDIT FUND INC.)
To: VERO BIOTECH INC. (F/K/A VERO BIOTECH LLC)
Reel/Frame 066186/0611 →
CHANGE OF NAME Recorded Feb 14, 2022
From: VERO BIOTECH LLC
To: VERO BIOTECH INC.
Reel/Frame 059085/0418 →
SECURITY INTEREST Recorded Dec 29, 2020
From: VERO BIOTECH LLC
To: RUNWAY GROWTH CREDIT FUND INC.
Reel/Frame 054866/0589 →
CHANGE OF NAME Recorded Jun 6, 2018
From: GENO LLC
To: VERO BIOTECH LLC
Reel/Frame 046304/0855 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2011
From: FINE, DAVID H.; ROUNBEHLER, DAVID P.; VASQUEZ, GREG
To: GENO LLC
Reel/Frame 026887/0879 →